Electronic Health Records-to-Electronic Data Capture Live Pilot Study
Data transfer technology from IgniteData finds 100% of data from vital signs and lab data were successful.
University College London Hospitals NHS Foundation Trust (UCLH), IgniteData and AstraZeneca have evaluated how Electronic Health Records (EHR) to Electronic Data Capture (EDC) data transfer could perform in a clinical trial setting. Four patients from an AstraZeneca-sponsored Phase III oncology study were enrolled into a live mirror study; and data from the first five of their visits were electronically transferred from UCLH’s EHR to a copy of the study database. In scope were three data intensive, structured domains: Vital Signs, Labs and Concomitant Medications. The live pilot found that IgniteData’s data transfer technology, Archer, could map 100% of Vital Signs and Labs data, and was able to successfully transfer 100% of mapped data from these domains.
IgniteData’s Archer enterprise-level solution combines system-agnostic interoperability between EHR and research systems. Archer stores no clinical data and provides a step-by-step review and approval process, so data ownership and control are not compromised.
HCP experience was measured using a 7-Lickert scale questionnaire: for user experience and perceived reduction in site burden, the overall score was positive and UCLH is optimistic about the future of EHR-to-EDC data transfer.
Dr Nick McNally, Managing Director, UCL/UCLH Research, said: “Evidence from our collaboration with IgniteData and AstraZeneca shows that laborious manual data transcription methods might realistically become a thing of the past as we see clear advances in data transfer technology. The UCLH team found Archer to be intuitive and easy to use. We were up and running after a short but comprehensive training session – exactly as we hoped.”
UCLH Director of Research Prof Bryan Williams added in a press release: “These are important results from a very successful pilot. The study highlights the value of having digital data in an EHR, which can then be rapidly transferred in a semi-automated way to other research systems.”
Dan Hydes, CEO at IgniteData, remarked, “IgniteData is extremely proud to have been selected as the technology vendor of choice for this collaboration with UCLH and AstraZeneca.”
The insights gained from this pilot study will inform ongoing collaborative plans to optimize CRF design, explore medical coding of EHR medications, and expand the use of EHR-to-EDC technology across various domains.
Reference: Evidence from Electronic Health Records-to-Electronic Data Capture live pilot study.Maidenhead UK, July 25, 2023.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
